Form 4 Filing for Arcutis Biotherapeutics, Inc.

This Form 4 filing details a transaction by Sue-Jean Lin, a director at Arcutis Biotherapeutics, Inc. On June 15, 2026, Ms. Lin sold 4,946 shares of Common Stock under a 10b5-1 trading plan adopted on December 4, 2025. The shares were sold at a weighted average price of $24.3807, with individual sales ranging from $24.045 to $24.62. Following this transaction, Ms. Lin directly owns 27,567 shares of Arcutis Biotherapeutics, Inc. The trading plan has an end date of February 19, 2027. This filing is based on the information provided in the SEC filing document.